Conference Coverage

Clinical Trials Should Be Standard of Care

US Department of Veterans Affairs (VA) lags, says oncologist Mark Klein, MD, but barriers can be overcome.


 

MINNEAPOLIS -- Clinical trials should be considered standard of care in oncology, the president of the Association of VA Hematology/Oncology (AVAHO) declared, and he urged colleagues to bypass obstacles and embrace them in patient care.

Clinical trials help many people, not just those in the studies, as they are indicators of robust oncology programs. “There’s a significant correlation between clinical trial activity [at sites] and improvement in survival in cancer,” said oncologist Mark Klein, MD, of the Minneapolis VA Health Care System and University of Minnesota, in a presentation at the 2019 annual meeting of AVAHO.

But the numbers suggest that the VA has lagged behind on the clinical trial front, Dr. Klein said. He pointed to internal statistics from 2001 to 2003, reported in 2010, which found clinical trial participation rates among men in the VA were lower (0.37%) than those of the national rates (0.74%).

Specifically, the VA and national participation rates were 1.16% and 0.30%, respectively, for colorectal cancer, 0.67% and 0.30% for lung cancer, 0.70% and 0.47% for prostate cancer, 0.52% and 0.74% for myeloma. According to Dr. Klein, lung and prostate cancer account for about half of all cancer diagnoses in the VA.

But the participation rates were much higher among the VA hospitals that took part in clinical trials, he said, at 2% for colorectal cancer, 1.4% for lung cancer, 2.5% for prostate cancer, 18.2% for myeloma and 2.07% overall. These numbers make it clear, he said, that it’s possible to improve: “We can do better.”

Dr. Klein pointed to other numbers that suggest the VA facilities that do participate in clinical trials typically do not take part in more than 1 or 2. In 2016, he said, an analysis found that open interventional trials were in progress at 82 VA facilities. About 35 facilities had little activity with only 1 trial in progress. “It has changed since then, but not dramatically.”

Meanwhile, he said, 2016 numbers also showed that about two-thirds of open interventional trials in the VA only included a single VA site. “We weren’t playing together, having consortia and working as a team.”

There are obstacles to improvement, he said, and fixes will take time. “It probably takes 5, 10-plus years,” he said.

These barriers include:

  • Lack of adequate trial offering. Changing regulations is key here;
  • Strict eligibility criteria. Easing the criteria and more effective screening are helpful;
  • Long distances to travel to cancer clinics. Telemedicine could make a difference on this front;
  • Patient concerns about being a “guinea pig.” Patient education can help;
  • Provider concerns such as worry about extra work. The VA can work to ease burdens and provide incentives for trial enrollment; and
  • High costs. Study sponsors may pay for trial drugs, helping facilities to lower expenses or even reach cost neutrality.

There are more solutions to boost participation, Dr. Klein said, including education, engagement and partnerships.

[embed:render:related:node:171979]

On the partnership front, he highlighted NAVIGATE, an interagency consortium of the VA and the National Cancer Institute. This collaboration aims to boost enrollment of VA patients in clinical trials, he said, and there are designated NAVIGATE sites across the country from coast to coast.

Pages

Recommended Reading

Characterization of Adverse Reactions to ‘4-week’ Nivolumab Dosing
AVAHO
Demographic Factors of Patients with Oligodendroglioma: A NCDB Analysis
AVAHO
A Focus on Implementation and Impact of a Pharmacy Driven Oral Chemotherapy Clinic
AVAHO
Identifying VA Cancer Patients for Clinical Trials: Use of an Umbrella Pre-Screening Protocol to Improve Enrollment in Oncology/Hematology Clinical Trials Within the VA Healthcare System
AVAHO
Prescribing Practices Based on Recommendations of the Veterans Health Administration’s National Precision Oncology Program
AVAHO
Primary Anatomical Site as a Prognostic Factor for Pleomorphic Liposarcoma
AVAHO
Primary Site and Other Prognostic Factors Affecting Myxoid Liposarcoma Survivorship
AVAHO
The Impact of Using Ideal Body Weight for Dosing of Intravenous Immune Globulin on Potential Grams Averted
AVAHO
Decreasing Chemotherapy Administration Wait Time for Veterans with Cancer: A Minneapolis VA Medical Center Quality Improvement Project
AVAHO
Cancer Care Coordination Perspectives of Veteran Patients with Cancer
AVAHO